Novel Drug Target for Inflammatory Myopathy

Request Number REQ7359380
Due Date February 14, 2018
Request for Proposal Details
RFP Title
Novel Drug Target for Inflammatory Myopathy
RFP Description

NineSigma, representing a global pharmaceuticals company, seeks a novel drug target for inflammatory myopathy. Proposals about specific pathogenic cells are also welcomed.


Inflammatory myopathy significantly exacerbates life prognosis, however R&D activities aimed at developing new drugs have not made sufficient progress because it is a rare disease. Recently, some studies reported that immunological mechanisms are involved in disease onset and progression. Also, specific auto-antibodies related to this disease have been identified.


Our client aims to develop a new drug for inflammatory myopathy to meet its unmet medical needs. Thus they have issued this open call to accelerate the development of innovative drug by combining our client’s expertise in drug development and the new targets to be proposed.



Key Success Criteria

Requirements of the drug target

The client anticipates a novel drug target that meets the following requirements.

  • Should be clearly shown by evidence based on genomic analysis or omics data that the target molecule/cell is a key factor for inflammatory myopathy pathogenesis. Its rationale should be demonstrated using at least one of the following approaches;
    • Phenotype in knockout or transgenic animals
    • Efficacy in disease models
    • In vitro assay using human patient specimens
  • Desirably, the drug target  plays a pathogenic role in specific subsets of inflammatory myopathy.
    • Inclusion body myositis
    • Anti-MDA5 antibody-positive dermatomyositis with interstitial pneumonia
    • Other treatment-resistant segments
  • Modality: The target should be druggable by one of the following: Antibodies, peptides, proteins, nucleic acid, small molecule compounds, or natural products.
    • Tool compounds such as antibodies and nucleic acid or lead compounds are also acceptable.
  • Development level: Should be in the early stage of exploratory research


In addition to the above target molecules and cells, combined proposals, with the addition of in vitro or in vivo evaluation system, biomarkers, and prediction tools, would be appreciated.



Approaches not of interest

The following approaches are not of interest:

  • Proposals for non-competitive, validated targets which are already in late-stage clinical trial or launched, including but not limited to targets listed below.
    • TNFα, IL-1α/β, CD20, IL-6, type I IFN, CD80/86, IL-17, etc.
  • Proposals for an evaluation system only


Preferred Collaboration types
Items to be submitted

Responses will use the Proposal Template which is linked to the “attachments” shown at the bottom of this page and include the following items:


  • Overview of the proposed drug target (characteristics, uniqueness, correlation with human diseases, etc.)
  • Target diseases (Subsets/segments should also be included, if anticipated.)
  • Rationale or data indicating validity as a drug target for above disease
  • Current R&D stage
  • Future R&D plans
  • Any requests concerning the collaboration
  • Current status of intellectual property related to the proposed technology
  • Research achievements



Area of Interest
Request Priority